Show simple item record

dc.contributor.authorMajidinia, M
dc.contributor.authorMihanfar, A
dc.contributor.authorRahbarghazi, R
dc.contributor.authorNourazarian, A
dc.contributor.authorBagca, BG
dc.contributor.authorAvci, CB
dc.date.accessioned2018-08-26T09:41:53Z
dc.date.available2018-08-26T09:41:53Z
dc.date.issued2016
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/58507
dc.description.abstractParkinson's disease (PD) is considered as a high prevalence neurodegenerative disorders worldwide. Pathologically, the demise of dopamine-producing cells, in large part due to an abnormal accumulation of the ?-synuclein in the substantia nigra, is one of the main causes of the disease. Up until now, many de novo investigations have been conducted to disclose the mechanisms underlying in PD. Among them, impacts of non-coding RNAs (ncRNAs) on the pathogenesis and/or progression of PD need to be highlighted. microRNAs (miRNAs) and long ncRNAs (lncRNAs) are more noteworthy in this context. miRNAs are small ncRNAs (with 18-25 nucleotide in length) that control the expression of multiple genes at post-transcriptional level, while lncRNAs have longer size (over 200 nucleotides) and are involved in some key biological processes through various mechanisms. Involvement of miRNAs has been well documented in the development of PD, particularly gene expression. Hence, in this current review, we will discuss the impacts of miRNAs in regulation of the expression of PD-related genes and the role of lncRNAs in the pathogenesis of PD. © 2016, Springer Science+Business Media Dordrecht.
dc.language.isoEnglish
dc.relation.ispartofMolecular Biology Reports
dc.subject3' UTR associated transcript RNA
dc.subjectadenosine triphosphatase
dc.subjectalpha synuclein
dc.subjectDJ 1 protein
dc.subjectenhancer RNA
dc.subjectleucine rich repeat kinase 2
dc.subjectlong untranslated RNA
dc.subjectmicroRNA
dc.subjectnatural antisense transcript RNA
dc.subjectparkin
dc.subjectphosphatase and tensin homolog induced kinase 1
dc.subjectphosphotransferase
dc.subjectprotein PARK9
dc.subjectunclassified drug
dc.subjectuntranslated RNA
dc.subjectlong untranslated RNA
dc.subjectmicroRNA
dc.subjectuntranslated RNA
dc.subjectbrain function
dc.subjectcentral nervous system disease
dc.subjectcentral nervous system function
dc.subjectdegenerative disease
dc.subjectgene expression
dc.subjectgene expression regulation
dc.subjecthuman
dc.subjectmacromolecule
dc.subjectmedical research
dc.subjectmolecular dynamics
dc.subjectmolecular pathology
dc.subjectneuropathology
dc.subjectnonhuman
dc.subjectParkinson disease
dc.subjectReview
dc.subjectRNA structure
dc.subjectRNA synthesis
dc.subjectdisease course
dc.subjectgene expression regulation
dc.subjectgenetics
dc.subjecthuman chromosome
dc.subjectParkinson disease
dc.subjectChromosomes, Human
dc.subjectDisease Progression
dc.subjectGene Expression Regulation
dc.subjectHumans
dc.subjectMicroRNAs
dc.subjectParkinson Disease
dc.subjectRNA, Long Noncoding
dc.subjectRNA, Untranslated
dc.titleThe roles of non-coding RNAs in Parkinson's disease
dc.typeArticle
dc.citation.volume43
dc.citation.issue11
dc.citation.spage1193
dc.citation.epage1204
dc.citation.indexScopus
dc.identifier.DOIhttps://doi.org/10.1007/s11033-016-4054-3


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record